retatrutide how to use vs Tirzepatide vs Semaglutide How to inject retatrutide: complete

Clinical Evidence for Combined Treatment Robust clinical trial data supports the use of metformin and semaglutide in combination for patients with type 2 diabetes and obesity

3 , -

Retatrutide (LY-3437943) is an investigational drug developed by Eli Lilly that acts as a triple hormone receptor agonist : GLP-1 (glucagon-like peptide-1) receptor agonist GIP (glucose-dependent insulinotropic polypeptide) receptor agonist Glucagon receptor agonist - read about why this is so important here This triagonist approach amplifies the metabolic impact seen with GLP-1 and GIP combinations like tirzepatide, while also leveraging glucagons thermogenic and energy-expending properties

Since Retatrutide is not approved for general consumer use in the UK, it is illegal to sell, supply, or use it for non-research purposes